Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease

PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DEDThis FDA-aligned trial targets the specific TNFR1 genotype to maximize treatment effects, with ~70% of clinical sites already activated and patients in the run-in phaseWith only 13% of DED patients experiencing sustained relief, Licaminlimab has the potential to offer a targeted precision solution for a highly unsatisfied market